ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Merck KGaA has acquired the Swiss start-up Chord Therapeutics for an undisclosed sum. Chord launched in 2020 with $16 million in funding to develop cladribine for the treatment of two rare neuroinflammatory diseases. Merck already markets cladribine under the name Mavenclad as a treatment for relapsing multiple sclerosis. The German firm says Chord will help it expand its pipeline of neurology drugs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter